[1] 王正颜,史仲华. 肝动脉栓塞化疗治疗肝癌[J]. 中华肿瘤杂志,1999,（1）l6：45.
[2] 中国抗癌协会肝癌专业委员会. 原发性肝癌规范化诊治专家共识[J]. 实用肝脏病杂志,2009,12（5）：321-328
[3] 中国抗癌协会肝癌专业委员会.原发性肝癌诊断标准[J]. 中华肝脏病杂志,2000,8：135.
[4] OHKUBO K,KATO Y,ICHIKAWA T,et a1. Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma[J]. Cancer,2002,15：94（10）：2663-2668.
[5] LAO CA,LEE CM,WU HC,et a1. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non Hodgkin’s lymphoma[J]. Br J Haematol,2002,116：166-169.
[6] ROSSI G. Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with hemotooncological neoplasias treated with chemotherapy[J]. Leuk Lymphoma,2003,44：759-766.
[7] 毛华,赵敏芳,宋卫生. 肝动脉化疗栓塞治疗原发性肝癌病人后细胞亚群改变[J]. 临床肝胆病杂志,1999,15：48-50.
[8] 张汀荣,许晨,茅卫东,等. 淋巴细胞亚群比例在原发性肝癌TACE,THPP前后动态变化的临床研究[J]. 中国癌症杂志,2002,23:12541-543.
[9] PARK JW,PARK KW,CHO SH,et a1. Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV related hepatocellular carcinoma：report of a prospective study[J]. Am J Gastroenterol,2005,100：2194-2199.
[10] 中华医学会肝病学分会和感染病学分会. 慢性乙型肝炎防治指南[J]. 实用肝脏病杂志,2006,9（1）：8-18. |
